S
Shazia Ali
Researcher at Abertawe Bro Morgannwg University Health Board
Publications - 15
Citations - 2553
Shazia Ali is an academic researcher from Abertawe Bro Morgannwg University Health Board. The author has contributed to research in topics: Ovarian cancer & Medicine. The author has an hindex of 9, co-authored 13 publications receiving 1334 citations. Previous affiliations of Shazia Ali include Université de Montréal & Duke University.
Papers
More filters
Journal ArticleDOI
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
David M. Weinreich,Sumathi Sivapalasingam,Thomas Norton,Shazia Ali,Haitao Gao,Rafia Bhore,Bret J Musser,Yuhwen Soo,Diana Rofail,Joseph Im,Christina Perry,Cynthia Pan,Romana Hosain,Adnan Mahmood,John D. Davis,Kenneth C. Turner,Andrea T. Hooper,Jennifer D. Hamilton,Alina Baum,Christos A. Kyratsous,Yunji Kim,Amanda Cook,Wendy Kampman,Anita Kohli,Yessica Sachdeva,Ximena Graber,Bari Kowal,Thomas DiCioccio,Neil Stahl,Leah Lipsich,Ned Braunstein,Gary Herman,George D. Yancopoulos +32 more
TL;DR: In this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline.
Journal ArticleDOI
The SLCO1B1*5 Genetic Variant is Associated with Statin-Induced Side Effects
Deepak Voora,Svati H. Shah,Ivan Spasojevic,Shazia Ali,Carol R. Reed,Benjamin A. Salisbury,Geoffrey S. Ginsburg +6 more
TL;DR: SLCO1B1*5 genotype and female sex were associated mild statin-induced side effects, and these findings expand the results of a recent genome-wide association study of statin myopathy with CK >3x normal to milder, stat in-induced, muscle side effects.
Journal ArticleDOI
Evinacumab for Homozygous Familial Hypercholesterolemia
Frederick J. Raal,Robert S. Rosenson,Laurens F. Reeskamp,G. Kees Hovingh,John J.P. Kastelein,Paolo Rubba,Shazia Ali,Poulabi Banerjee,Kuo-Chen Chan,Daniel A. Gipe,Nagwa Khilla,Robert Pordy,David M. Weinreich,George D. Yancopoulos,Yi Zhang,Daniel Gaudet +15 more
TL;DR: In patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy, the reduction from baseline in the LDL cholesterol level in the evinacumab group, as compared with the small increase in the placebo group, resulted in a between-group difference of 49.0 percentage points at 24 weeks.
Journal ArticleDOI
Evinacumab in Patients with Refractory Hypercholesterolemia
Robert S. Rosenson,Lesley J. Burgess,C. Ebenbichler,Seth J. Baum,Erik S.G. Stroes,Shazia Ali,Nagwa Khilla,Robert Hamlin,Robert Pordy,Yuping Dong,Vladimir Son,Daniel Gaudet +11 more
TL;DR: In patients with refractory hypercholesterolemia, the use of evinacumab significantly reduced the LDL cholesterol level, by more than 50% at the maximum dose.
Journal Article
Progesterone Receptor Promoter +331A Polymorphism is Associated with a Reduced Risk of Endometrioid and Clear Cell Ovarian Cancers
Andrew Berchuck,Joellen M. Schildkraut,Robert M. Wenham,Brian Calingaert,Shazia Ali,Amy Henriott,Susan Halabi,Gustavo C. Rodriguez,Dorota M. Gertig,David M. Purdie,Livia Kelemen,Amanda B. Spurdle,Jeffrey R. Marks,Georgia Chenevix-Trench +13 more
TL;DR: Findings suggest that the +331G/A progesterone receptor promoter polymorphism may modify the molecular epidemiologic pathway that encompasses both the development of endometriosis and its subsequent transformation into endometioid/clear cell ovarian cancer.